Scholars Central

Review articlePublished 13 Feb 2019

Final Efficacy Results of a Randomized Phase II Study of Recombinant Interleukin-21 Compared to Dacarbazine in Patients with Recurrent or Metastatic Melanoma

Authors: Teresa M. Petrella, Catalin Mihalcioiu, Jose Monzon, Elaine McWhirter, Karl Belanger, Kerry J. Savage, Xinni Song, Omid Hamid, Tina Cheng, Mary Davis, Christopher W. Lee, Alan Spatz, Linda Hagerman, Bingshu E. Chen, Janet Dancey

1Sunnybrook Odette Cancer Centre, Toronto, Canada; 2Department of Oncology, McGill University, Montreal, Canada; 3Canadian Cancer Trials Group, Queen’s University, Kingston, Canada; 4Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada; 5Hopital Notre-Dame du CHUM, Montreal, Canada; 6BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada; 7Ottawa Health Research Institute-General Division, Ottawa, Canada; 8The Angeles Clinic and Research Institute, Los Angeles, USA; 9Tom Baker Cancer Centre, Calgary, Canada; 10QEII Health Sciences Centre, Halifax, Canada; 11BC Cancer Agency, Fraser Valley Cancer Centre, Surrey, Canada; 12McGill University & Lady Davis Institute for Medical Research, Montreal, Canada

Journal of Oncology Research and Treatment

Volume 4 · Issue 1 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: Interleukin-21(IL-21) is a T-cell derived cytokine with antitumour activity dependent on NK cells or CD8+ T cells. A previous phase II study demonstrated an overall response rate (ORR) of 22.5% in previously untreated patients with metastatic melanoma. We conducted a multi-centre randomized phase II study in metastatic melanoma patients to evaluate the efficacy, toxicity, immunogenicity and biomarkers associated with response to IL-21 versus dacarbazine (DTIC). Methods: Eligible patients: Recurrent, non-resectable or metastatic melanoma patients were treated with either IL-21, 30 μg/kg/day dose intravenous (IV) daily x 5 days, weeks 1, 3, 5, q 8 weeks or dacarbazine (DTIC) 1000 mg/ m2 IV day 1, q 3 weeks. The primary objective was to compare progression free survival (PFS). Results: 64 patients were randomized, 32 in the IL-21 arm and 32 in the DTIC arm. In the treated population, PFS (1.87 months for IL-21, 2.04 months for DTIC) and ORR {IL-21: 13.3% (95% CI: 3.8 to 30.7), DTIC: 14.3% (95% CI: 4.0 to 32.7)} was similar in both groups. Most common adverse events (AEs) in Arm 1 (IL-21) were nausea (38%), fatigue (56%), fever (34%), maculo-papular rash (34%), and pruritis (38%). In Arm 2 (DTIC) the most common AEs were fatigue (39%), constipation (29%), and nausea (21%). Biomarker studies showed no correlation of sCD25 changes and PFS outcome (HR=0.86, 95% CI. 0.73 to 1.02). Conclusions: Despite encouraging efficacy in prior phase I/II studies, the results suggest that IL-21 is comparable to DTIC in this specific patient population.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Oncology Research and Treatment.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Oncology Research and Treatment
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Teresa M. Petrella”
  • BylineArticles whose byline prints “Catalin Mihalcioiu”
  • BylineArticles whose byline prints “Jose Monzon”
  • BylineArticles whose byline prints “Elaine McWhirter”
  • BylineArticles whose byline prints “Karl Belanger”
  • BylineArticles whose byline prints “Kerry J. Savage”
  • BylineArticles whose byline prints “Xinni Song”
  • BylineArticles whose byline prints “Omid Hamid”